Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

@article{Ho2013ShorttermOO,
  title={Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.},
  author={Vincent Ho and Steven Yeh and Timothy W. Olsen and Chris S Bergstrom and Jiong Yan and Blaine E Cribbs and George Baker Hubbard},
  journal={American journal of ophthalmology},
  year={2013},
  volume={156 1},
  pages={23-28.e2}
}
PURPOSE To report results of aflibercept therapy in eyes with neovascular age-related macular degeneration previously treated with bevacizumab, ranibizumab, or both. DESIGN Retrospective, interventional, noncomparative, consecutive case series. METHODS Ninety-six eyes from 85 patients with neovascular age-related macular degeneration who previously had received bevacizumab, ranibizumab, or both were treated with aflibercept monthly for 3 months followed by a fourth injection within 2 months… CONTINUE READING